Post-partum Depression: an Integrated Molecular-pharmaco-imaging Study (DRACULA 1)
The Role of the Glutamatergic Neurotransmission in Post-partum Depression: an Integrated Molecular-pharmaco-imaging Study
Post-partum depression (PPD) is a prevalent subtype of major depressive disorder that causes a significant distress to the woman and substantial impact on the whole family. Many studies implicate the glutamatergic system in pathological processes relevant to PPD disorders. There is evidence that cell adhesion molecules (CAMs) play a key role in how glutamatergic circuits wire up during development and how glutamatergic synapses, once formed, operate. However, it is unclear how dysregulation in diverse CAMs alter glutamatergic circuitries responsible for emotional and social behavior.
Here, the investigators propose to evaluate the molecular and neurobiological underpinnings of PPD focusing on CAMs at glutamatergic synapses by using an integrated approach from mouse models to human patients. Moreover, the investigators will also perform a pilot study to investigate the impact of selective antidepressants, known to be linked to CAMs, in both human and mice.
調査の概要
詳細な説明
Patients will be recruited by the physician in charge of the study or collaborators of the S.C. Neonatology and Neonatal Intensive Care Unit of the IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation upon referral from the S.C. Psychiatry of the same institution. In the study, exposure to citalopram treatment will be 12 weeks with follow-up every 4 weeks. At each participant, at the time of enrollment, will be assigned a unique code so that only the local investigators can trace the subject's identity. As part of a scheduled visit to assess the clinical diagnosis, the PPD patient will be offered to participate in the study, after the appropriate signing of informed consent, the verification of absence of criteria for exclusion and existence of the study inclusion criteria. If these criteria are met, some demographic and clinical medical history of the women with PPD will be collected, as already provided by clinical practice for the management of the disease. Patients will undergo MRI scanning at baseline at the S.C. Neuroradiology of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and will begin the pharmacological treatment with citalopram. It is emphasized that the administration of citalopram therapy for the treatment of depressive symptomatology will be proposed and carried out in the patient due to clinical needs, based on the judgment of the competent physician and as would already be the case in practice, thus completely independent of participation or non-participation in the present study. Neuroimaging data will be obtained with a Philips 3T magnetic resonance imaging MRI machine. For each patient enrolled in the study, a structural T1 sequence (3D MPRAGE) is acquired.
T1-weighted MRI images will be used to study the differences brain morphology, including the volumes of gray matter (GM) and white matter (WM) and voxel-based morphometry. In a comparison parallel between regions of interest (ROIs), regional volumes will be estimated using the automated anatomical labeling atlas (AAL) as a reference, with emphasis on the dorsolateral PFC (DL)/ventrolateral (VL), cingulate cortex, amygdala and hippocampus. Further regional analysis will allow estimation, in addition to cortical volumes and subcortical volumes, cortical thickness, cortical surface area, and the cortical gyrification of the Desikan-Killiany atlas regions. During treatment with citalopram, patients will be visited, as per standard clinical practice, every 4 weeks. At each of these follow-up visits will be administered to patients by medical specialists the Brief Psychiatric Rating Scale (BPRS) and the Hamilton Depression Rating Scale (HAM- D) to study symptomatology depression. Patients will be, instead, self-administered in Italian language the Maternal Postnatal Attachment Scale (MPAS) and the Parental Stress Index (PSI) to investigate mother-child attachment and parental stress. The time scheduled for completion of both scales will be about 40 minutes. At 12 weeks, as per practice, the MRI scan will be repeated at the S.C. Neuroradiology Department of the Foundation. The following variables will be collected as part of this study: socio-demographic variables (age, schooling, socio-economic);
- clinical/anamnestic variables (age of onset, duration of untreated treated, drug therapy, comorbidities, familiarity, substance abuse/dependence);
- BPRS and HAM-D scales scores for symptomatology assessment (T0, T1, T2, T3);
- MPAS and PSI scales scores for the assessment of mothers child attachment. (T0, T1, T2, T3);
- MRI scan data (T0, T3): the images will be used to study brain morphological differences, including GM and WM volumes, and voxel-based morphometry. In a parallel comparison between regions of interest (ROI), regional volumes will be estimated using as a reference the automated anatomical labeling atlas (AAL), with particular attention to the dorsolateral (DL)/ventrolateral (VL) PFC, cingulate cortex, amygdala and hippocampus. A further regional analysis will make it possible to estimate, in addition to cortical and subcortical volumes, the thickness cortical, cortical surface area and cortical gyrification of the Desikan-Killiany atlas regions.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Domenica mercadante, doctor
- 電話番号:02 5503 2234
- メール:domenica.mercadante@policlinico.mi.it
研究場所
-
-
Michigan
-
Milan、Michigan、イタリア、20100
- 募集
- Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
-
コンタクト:
- Paolo Brambilla, Professor
- 電話番号:+ 39 02 55032717
- メール:paolo.brambilla1@unimi.it
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Women, aged 18 years to 40 years of age or older, with PPD who will be enrolled by the S.C. Neonatology and Neonatal Intensive Care Unit of the IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation upon referral from the S.C. Psychiatry of the same institution.
説明
Inclusion Criteria:
- Age between 18 and 40 years;
- female gender;
- PPD diagnosed by DSM-5 structured clinical interview support (SCID-5) by trained medical personnel;
- comorbidity with metabolic syndrome, which can lead to brain damage and cognitive flaws;
- need to start citalopram therapy for clinical needs (and therefore independent of study participation) or already on therapy for no more than two weeks;
- moderate to severe depression according to the 17-item HAM-D (score 14-24);
- absence of disabling medical and/or neurological conditions, including heart attacks, brain injuries, neurodegenerative diseases, head trauma with loss of consciousness for more than 30 minutes;
- Absence of concomitant psychiatric therapies (antidepressants, antipsychotics of the first and second generation and mood stabilizers);
- absence of contraindications for MRI scanning;
- patients who have signed informed consent.
Exclusion Criteria:
- age below 18 years or above 40 years;
- diagnosis different from PPD based on SCID-5;
- absence of metabolic syndrome;
- low depression according to the 17-item HAM-D (score less than 14);
- presence of disabling medical and/or neurological conditions, including heart attacks, brain injuries, neurodegenerative diseases, head trauma with loss of consciousness for more than 30 minutes;
- presence of concomitant drug therapies (antidepressants, first- and second-generation antipsychotics and mood stabilizers);
- presence of contraindications for MRI scanning;
- presence of contraindications for citalopram;
- patients who have not signed informed consent.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:CASE_ONLY
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Women with Post-Partum Depression
15 women with PPD referred to the S.C. Psychiatry of IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation and referred to the S.C. Neonatology and Neonatal Intensive Care Unit of the same institution for enrollment. |
Patients will be administered citalopram, regardless of inclusion or non-inclusion in this study, on medical indication, as per normal clinical practice for disease management and according to the Summary of Product Characteristics (SPC). Patients will have two MRI scans done (at baseline and at 12 weeks after the start of therapy) to assess: brain volumetry, tissue amount of gray matter - GM - and white matter - WM |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline in Total White Matter (WM) Volume at Week 12
時間枠:Baseline and week 12
|
Total white matter volume, expressed in cubic millimeters (mm³), will be estimated from 3D T1-weighted (MPRAGE) images acquired on a Philips 3T MRI scanner, using tissue segmentation in SPM12 (voxel-based morphometry). A single value per participant (total WM volume) will be computed at each time point, and the change from baseline (week 12 minus baseline) will be reported. |
Baseline and week 12
|
|
Change From Baseline in Total Gray Matter (GM) Volume at Week 12
時間枠:Baseline and week 12
|
Total gray matter volume, expressed in cubic millimeters (mm³), will be estimated from 3D T1-weighted (MPRAGE) images acquired on a Philips 3T MRI scanner, using tissue segmentation in SPM12 (voxel-based morphometry). A single value per participant (total GM volume) will be computed at each time point, and the change from baseline (week 12 minus baseline) will be reported. |
Baseline and week 12
|
|
Change From Baseline in Total Brain Volume at Week 12
時間枠:Baseline and week 12
|
Total brain volume, expressed in cubic millimeters (mm³), will be calculated as the sum of total gray matter and total white matter volumes obtained from SPM12 segmentation of 3D T1-weighted (MPRAGE) images acquired on a Philips 3T MRI scanner. A single value per participant will be computed at each time point, and the change from baseline (week 12 minus baseline) will be reported. |
Baseline and week 12
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline in Hamilton Depression Rating Scale (HAM-D, 21-item) Total Score at Week 12
時間枠:Baseline and week 12
|
Depressive symptom severity will be assessed with the clinician-administered 21-item Hamilton Depression Rating Scale (HAM-D). Higher scores indicate more severe depression. The change from baseline (week 12 minus baseline) in total score will be reported. |
Baseline and week 12
|
|
Percentage of Participants Responding to Treatment at Week 12
時間枠:Baseline and week 12
|
Response is defined as a reduction of at least 30% in the 21-item Hamilton Depression Rating Scale (HAM-D) total score at week 12 compared with baseline. Higher HAM-D scores indicate more severe depression. The percentage of participants meeting the response criterion will be reported. |
Baseline and week 12
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Adverse Events Related to Citalopram
時間枠:From baseline through week 12
|
Number of participants experiencing at least one serious or non-serious adverse event judged by the medical staff to be related to citalopram, from treatment start through week 12. |
From baseline through week 12
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Postpartum Depression: Action Towards Causes and Treatment (PACT) Consortium. Heterogeneity of postpartum depression: a latent class analysis. Lancet Psychiatry. 2015 Jan;2(1):59-67. doi: 10.1016/S2215-0366(14)00055-8. Epub 2015 Jan 8.
- Boku S, Nakagawa S, Toda H, Hishimoto A. Neural basis of major depressive disorder: Beyond monoamine hypothesis. Psychiatry Clin Neurosci. 2018 Jan;72(1):3-12. doi: 10.1111/pcn.12604. Epub 2017 Oct 19.
- Asahina H, Masuba A, Hirano S, Yuri K. Distribution of protocadherin 9 protein in the developing mouse nervous system. Neuroscience. 2012 Dec 6;225:88-104. doi: 10.1016/j.neuroscience.2012.09.006. Epub 2012 Sep 11.
- Bambico FR, Belzung C. Novel insights into depression and antidepressants: a synergy between synaptogenesis and neurogenesis? Curr Top Behav Neurosci. 2013;15:243-91. doi: 10.1007/7854_2012_234.
- Bruining H, Matsui A, Oguro-Ando A, Kahn RS, Van't Spijker HM, Akkermans G, Stiedl O, van Engeland H, Koopmans B, van Lith HA, Oppelaar H, Tieland L, Nonkes LJ, Yagi T, Kaneko R, Burbach JP, Yamamoto N, Kas MJ. Genetic Mapping in Mice Reveals the Involvement of Pcdh9 in Long-Term Social and Object Recognition and Sensorimotor Development. Biol Psychiatry. 2015 Oct 1;78(7):485-95. doi: 10.1016/j.biopsych.2015.01.017. Epub 2015 Feb 7.
- Cingolani LA, Thalhammer A, Yu LM, Catalano M, Ramos T, Colicos MA, Goda Y. Activity-dependent regulation of synaptic AMPA receptor composition and abundance by beta3 integrins. Neuron. 2008 Jun 12;58(5):749-62. doi: 10.1016/j.neuron.2008.04.011.
- Davis AD, Hassel S, Arnott SR, Harris J, Lam RW, Milev R, Rotzinger S, Zamyadi M, Frey BN, Minuzzi L, Strother SC, MacQueen GM, Kennedy SH, Hall GB. White Matter Indices of Medication Response in Major Depression: A Diffusion Tensor Imaging Study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 Oct;4(10):913-924. doi: 10.1016/j.bpsc.2019.05.016. Epub 2019 Jun 12.
- Duric V, Banasr M, Stockmeier CA, Simen AA, Newton SS, Overholser JC, Jurjus GJ, Dieter L, Duman RS. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. Int J Neuropsychopharmacol. 2013 Feb;16(1):69-82. doi: 10.1017/S1461145712000016. Epub 2012 Feb 17.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- DRACULA 1
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。